Drug General Information
Drug ID
D09GEK
Former ID
DNCL002360
Drug Name
ASP3026
Drug Type
Small molecular drug
Indication Late-stage B-cell lymphoma [ICD9: 140-199, 202.8, 210-229; ICD10:C00-C75, C7A, C7B, C81-C86, C85.1, D10-D36, D3A] Phase 1 [523558], [542706]
Company
Astellas Pharma
Structure
Download
2D MOL

3D MOL

Formula
C29H40N8O3S
InChI
InChI=1S/C29H40N8O3S/c1-21(2)41(38,39)27-8-6-5-7-25(27)33-29-31-20-30-28(34-29)32-24-10-9-23(19-26(24)40-4)36-13-11-22(12-14-36)37-17-15-35(3)16-18-37/h5-10,19-22H,11-18H2,1-4H3,(H2,30,31,32,33,34)
InChIKey
MGGBYMDAPCCKCT-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) ALK tyrosine kinase receptor Target Info Modulator [542706]
KEGG Pathway Non-small cell lung cancer
WikiPathways Differentiation Pathway
References
Ref 523558ClinicalTrials.gov (NCT01401504) Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors. U.S. National Institutes of Health.
Ref 542706(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7740).
Ref 542706(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7740).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.